New York, NY (November, 21, 2017) — This Thanksgiving week, WCBS-TV will air “The Resilient Heart,” a feature documentary that explores the keys to eradicating heart disease on a worldwide scale. The film will air on Friday, November 24, from 10 am to 11 am on WCBS (channel 2) and on Sunday, November 26, from 10 pm to 11 pm on WLNY (channels 10/55).

Using virtual reality training to restore motor function after a stroke is just as effective as traditional physical therapy, reports a new study published in the medical journal Neurology.

Aramark, a food service company that serves two billion meals each year in the U.S., has reported second-year results from a program aimed at serving healthier food across workspaces, hospital cafes, colleges and universities.

New research suggests greater amounts of high-density lipoprotein (HDL) cholesterol don’t cut the risk of cardiovascular disease (CVD) when low-density lipoprotein (LDL) cholesterol levels stay the same.

The incidence of young athletes experiencing sudden cardiac arrest during competitive sporting events is slim—just 0.76 cases in 100,000 athlete-years—but it does happen, according to one team of Canadian researchers who analyzed dozens of out-of-hospital cardiac arrests in an effort to dissect the underlying causes of these tragedies.

While recent discussion has centered on the lower threshold for hypertension (130/80 millimeters of mercury) and what it means for clinical practice, many of the implications for the new guidelines rely on the assumption that blood pressure is being measured correctly in the first place.

DUBLIN — November 20, 2017 — Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. commercial launch for its portfolio of Azure(TM) pacemakers with BlueSync(TM)technology.

A new real-world analysis of adults with type 2 diabetes and established cardiovascular disease (CVD) shows adult patients who initiated therapy with INVOKANA® (canagliflozin) or another sodium glucose cotransporter-2 inhibitor (SGLT2i) had a 43 percent reduced risk for all-cause mortality (ACM) and hospitalization for heart failure (HHF) after an average of 1.6 years, compared to similar patients who initiated treatment with a non-SGLT2i medication using an intent-to-treat (ITT) approach.